RedHill Biopharma Ltd.RDHL

時価総額

PER

消化器系・感染症・腫瘍領域に注力するバイオ医薬品の新興企業、2009年設立。GI関連製品Taliciaを米国で商業化、臨床段階の候補薬5本を保有。2023年2月にMovantikをHCRMに売却。米国中心に展開、UAEで2023年承認・2024年発売。

概要財務

サマリーテーブルに戻る

	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Income (loss)	-46	-39	-42	-76	-98	-72	24	-8
Adjustments for share-based payments	2	3	3	4	10	6	2	1
Depreciation	0	0	1	2	2	2	1	1
Amortization of intangible assets	-	-	0	-	-	-	1	0
Gains from the transfer of rights in Movantik and extinguishment of debt obligations, see below	-	-	-	-	-	-	-56	-
Gains From Early Termination Of Leases And Impairment Of Fixed Assets	-	-	-	-	-	-	-	-0
Adjustment For Non Cash Loss From Global Termination Agreement.	-	-	-	-	-	-	-	2
Fair value (gains) losses on derivative financial instruments, recognition of day 1 loss and changes in royalty obligation	-	-	-	-	-	-	-	-8
Adjustments For Loss From Modification Of Warrants Terms As Part Of A New Issuance.	-	-	-	-	-	-	1	-
Issuance costs in respect of warrants	-	-	-	-	-	-	2	1
Exchange differences and revaluation of bank deposit	-	-	-	-	-	-	-	-0
Total adjustments in respect of income and expenses not involving cash flow	-3	3	4	19	34	34	-44	-3
Decrease (increase) in trade receivables	-1	1	-0	-27	-3	-3	32	0
Decrease in prepaid expenses and other receivables	-	-	-	-	-	-	-	2
Decrease in inventories	-1	-0	-1	-5	-8	4	2	1
Decrease in accounts payable	5	-1	1	7	0	-7	-1	-2
Decrease in accrued expenses and other liabilities	3	1	-1	19	-3	-3	-13	3
Increase (decrease) in allowance for deductions from revenue	-	-	-	17	12	17	-37	-1
Total changes in assets and liability items	-4	-1	2	-8	1	-8	16	-2
Net cash used in operating activities	-45	-34	-41	-49	-65	-29	-36	-9
Purchase of fixed assets	0	0	0	0	0	0	0	0
Change in investment in current bank deposits	-	-	-	-	-	-	0	-
Net cash provided by (used in) investing activities	-19	5	5	-36	-8	8	0	-0
Proceeds from issue of ordinary shares	-	-	-	24	79	24	14	8
Repayment of payable in respect of intangible asset purchase	-	1	-	-	7	11	7	-
Decrease in restricted cash	-	-	-	4	-	-	15	1
Payment of principal with respect to lease liabilities	-	-	1	2	2	1	1	1
Net cash provided by financing activities	26	42	36	84	73	11	21	8
DECREASE IN CASH AND CASH EQUIVALENTS	-38	13	-0	0	0	-9	-14	-1
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	0	-0	0	0	-0	-0	-0	0
Supplemental Information Interest Received in Cash	0	1	1	0	0	0	0	0
Supplemental Information Interest Paid In Cash	-	-	0	7	11	8	0	0
Decrease In Lease Liability From Early Termination Of Lease	-	-	-	-	-	1	5	0
Decrease in Intangible asset	-	-	-	-	-	-	-60	-
Decrease in Inventories	-	-	-	-	-	-	-4	-
Decrease in Payable in respect of Intangible asset	-	-	-	-	-	-	5	-
Decrease in Borrowing	-	-	-	-	-	-	115	-
Gains from the transfer of the rights in Movantik and extinguishment of debt obligations	-	-	-	-	-	-	56	-